TABLE 1

Accumulative qPCR findings in pretreated chronic Chagas disease patients from DNDi-CH-E1224-001 and MSF-DNDi PCR sampling optimization clinical studiesa

Clinical trial, locality, and parameterValue(s) for:
S1S2S1+S2S3S1+S2+S3
qPCR1+2qPCR1+2+3qPCR1+2qPCR1+2+3qPCR1+2+3
DNDi-CH-E1224-001
    CBBA
        N29429428928929474294
        No. (%) positive161 (54.8)178 (60.5)155 (53.6)171 (59.2)205 (69.7)19 (25.7)224 (76.2)
        No. (%) quantifiable31 (19.3)31 (17.4)26 (16.8)26 (15.2)44 (21.5)0 (0.0)44 (19.6)
        Median (IQR) (par. eq./ml)2.6 (1.9–3.4)2.6 (1.9–3.4)2.7 (2.0–3.9)2.7 (2.0–3.9)2.6 (2.0–3.5)2.6 (2.0–3.5)
    Tarija
        N25725725725725753257
        No. (%) positive153 (59.5)163 (63.4)142 (55.3)156 (60.7)190 (73.9)10 (18.9)200 (77.8)
        No. (%) quantifiable37 (24.2)37 (22.7)32 (22.5)33 (21.2)49 (25.8)0 (0.0)49 (24.5)
        Median (IQR) (par. eq./ml)2.4 (2.0–3.4)2.4 (2.0–3.4)3.0 (2.4–3.6)3.0 (2.2–3.6)2.6 (2.0–3.6)2.6 (2.0–3.6)
MSF–DNDi sampling study
    Aiquile
        N196195201176205
        No. (%) positive144 (73.5)150 (76.9)171 (85.1)128 (72.7)185 (90.2)
        No. (%) quantifiable34 (23.6)40 (26.7)51 (29.8)29 (22.7)61 (33.0)
        Median (IQR) (par. eq./ml)2.4 (1.9–4.5)2.9 (1.9–4.9)2.8 (1.9–4.8)3.2 (2.0–4.8)3.0 (2.0–4.7)
  • a S1-3, samples 1 to 3; qPCR1-3, qPCR replicates 1 to 3; CBBA, Cochabamba; N, number of samples.